نتائج البحث - Hyeon‐Seok Eom

تنقيح النتائج
  1. 1
    4-1BB immunotherapy: advances and hurdles

    4-1BB immunotherapy: advances and hurdles حسب Rohit Kumar Singh, Young Ho Kim, Sang-Jin Lee, Hyeon‐Seok Eom, Beom K. Choi

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions

    Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions حسب Ronjon Chakraverty, Hyeon‐Seok Eom, Jessica Sachs, Jennifer Buchli, Pete Cotter, Richard Hsu, Guiling Zhao, Megan Sykes

    منشور في 2006
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Elevated Red Blood Cell Distribution Width as a Simple Prognostic Factor in Patients with Symptomatic Multiple Myeloma

    Elevated Red Blood Cell Distribution Width as a Simple Prognostic Factor in Patients with Symptomatic Multiple Myeloma حسب Hyewon Lee, Sun‐Young Kong, Ji Yeon Sohn, Hyoeun Shim, Hye Sun Youn, Sang Eun Lee, Hyun Ju Kim, Hyeon‐Seok Eom

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma

    Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma حسب J. Lee, Cheolwon Suh, Hye Jin Kang, Baek‐Yeol Ryoo, Jooryung Huh, Young Hyeh Ko, Hyeon‐Seok Eom, Kihyun Kım, K. Park, W. S. Kim

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Adenovirus Expressing Both Thymidine Kinase and Soluble PD1 Enhances Antitumor Immunity by Strengthening CD8 T-cell Response

    Adenovirus Expressing Both Thymidine Kinase and Soluble PD1 Enhances Antitumor Immunity by Strengthening CD8 T-cell Response حسب Seung-Pil Shin, Hye-Hyun Seo, Jae-Hun Shin, Hyung-Bae Park, Dong-Pyo Lim, Hyeon‐Seok Eom, Yong‐Soo Bae, In-Hoo Kim, Kyungho Choi, Sang-Jin Lee

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008

    Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008 حسب Hyeon Jin Park, Eunhye Park, Kyu‐Won Jung, Hyun-Joo Kong, Young‐Joo Won, Joo Young Lee, Jong Hyung Yoon, Byung-Kiu Park, Hyewon Lee, Hyeon‐Seok Eom, Sohee Park

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models

    Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models حسب Jae Hun Shin, Hyung Bae Park, Yu Mi Oh, Dong Pyo Lim, Ji Eun Lee, Hae Hyun Seo, Sang Jin Lee, Hyeon Seok Eom, In-Hoo Kim, Seung Hoon Lee, Kyungho Choi

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Nationwide Statistical Analysis of Lymphoid Malignancies in Korea

    Nationwide Statistical Analysis of Lymphoid Malignancies in Korea حسب Hye Won Lee, Hyeon Jin Park, Eunhye Park, Hee Young Ju, Chang‐Mo Oh, Hyun‐Joo Kong, Kyu‐Won Jung, Byung‐Kiu Park, Eunyoung Lee, Hyeon‐Seok Eom, Young‐Joo Won

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

    Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL حسب Fritz Offner, Olga Samoilova, Evgenii A. Osmanov, Hyeon‐Seok Eom, Max S. Topp, João Raposo, Viacheslav Pavlov, Deborah Ricci, Shalini Chaturvedi, Eugene Zhu, Helgi van de Velde, Christopher Enny, Aleksandra Rizo, Burhan Ferhanoğlu

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012

    Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012 حسب Eunhye Park, Hyewon Lee, Young‐Joo Won, Hee Young Ju, Chang‐Mo Oh, Cecile Ingabire, Hyun-Joo Kong, Byung-Kiu Park, Ju Young Yoon, Hyeon‐Seok Eom, Eunyoung Lee, Hyeon Jin Park

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma

    Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma حسب Tycel Phillips, Henry Chan, Constantine S. Tam, Alessandra Tedeschi, Patrick B. Johnston, Sung Yong Oh, Stephen Opat, Hyeon‐Seok Eom, Heather Allewelt, J. C. Stern, Ziwen Tan, William Novotny, Jane Huang, Judith Trotman

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma حسب Ken Ohmachi, Nozomi Niitsu, Toshiki Uchida, Seok Jin Kim, Kiyoshi Ando, Naoki Takahashi, Naoto Takahashi, Naokuni Uike, Hyeon Seok Eom, Yee Soo Chae, Takashi Terauchi, Ukihide Tateishi, Mitsuaki Tatsumi, Won Seog Kim, Kensei Tobinai, Cheolwon Suh, Michinori Ogura

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Matched‐pair analysis comparing the outcomes of primary breast and nodal diffuse large B‐cell lymphoma in patients treated with rituximab plus chemotherapy

    Matched‐pair analysis comparing the outcomes of primary breast and nodal diffuse large B‐cell lymphoma in patients treated with rituximab plus chemotherapy حسب Ho‐Young Yhim, Jin Seok Kim, Hye Jin Kang, Seok Jin Kim, Won Seog Kim, Chul Won Choi, Hyeon Seok Eom, Jeong‐A. Kim, Jae Hoon Lee, Jong-Ho Won, Hyeok Shim, Jooryung Huh, Daeho Lee, Cheolwon Suh, Jae‐Yong Kwak

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas

    A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas حسب Seung Ju Kim, Dong-Yeop Shin, Jin Sung Kim, Dok Hyun Yoon, W.S. Lee, H. Lee, Young-Rok Do, Hye Jin Kang, Hyeon‐Seok Eom, Young Hyeh Ko, S.H. Lee, Hae Young Yoo, Min Eui Hong, Cheolwon Suh, Woo Seob Kim

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia

    Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukem... حسب J.-H. Yoon, Ho‐Young Yhim, Jae‐Yong Kwak, Jae‐Sook Ahn, Deok‐Hwan Yang, J.-J. Lee, Se Joo Kim, J.-S. Kim, So Jeong Park, Chul Won Choi, Hyeon‐Seok Eom, S.-K. Park, Soo Young Choi, S.-H. Kim, D.-W. Kim, S. Lee

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial

    Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial حسب Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Hye Jin Kang, Hye Won Lee, Hyeon‐Seok Eom, Jung Yong Hong, Junhun Cho, Young Hyeh Ko, Jooryung Huh, Woo‐Ick Yang, Weon Seo Park, Seung‐Sook Lee, Cheolwon Suh, Won Seog Kim

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study

    Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for... حسب Seok Jin Kim, Kihyun Kım, Byung‐Soo Kim, Chul Yong Kim, Cheolwon Suh, Jooryung Huh, Sang-Wook Lee, Jin Seok Kim, Jaeho Cho, Gyeong-Won Lee, Ki Mun Kang, Hyeon Seok Eom, Hong Ryull Pyo, Yong Chan Ahn, Young Hyeh Ko, Won Seog Kim

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed/refractory multiple myeloma

    Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed/refractory multiple myeloma حسب Soo Chin Ng, Joon‐Ho Moon, Sung Soo Park, Youngil Koh, Ji Hyun Lee, Hyeon‐Seok Eom, Ho‐Jin Shin, Sung Hoon Jung, Young Rok, Gilbert Wilfred, Azlan Husin, Hyo Jung Kim, S A W Fadilah, Myung-Won Lee, Hye-won Heo, Kihyun Kım, Suporn Chuncharunee

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

    Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study حسب Huiqiang Huang, Jun Zhu, Ming Yao, Tae Min Kim, Dok Hyun Yoon, Seok‐Goo Cho, Hyeon Seok Eom, Soon Thye Lim, Su-Peng Yeh, Yuqin Song, Yok‐Lam Kwong, Jin Seok Kim, Jie Jin, Yuankai Shi, Hye‐Jin Kim, Qing Min, Tianyuan Zhou, Grace Gao, Zong-qi Dong, Ming Qi, Won Seog Kim

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

    Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma حسب Stephen M. Ansell, John Radford, Joseph M. Connors, Monika Długosz‐Danecka, Won-Seog Kim, Andrea Gallamini, Radhakrishnan Ramchandren, Jonathan W. Friedberg, Ranjana H. Advani, Martin Hutchings, Andrew M. Evens, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Hyeon‐Seok Eom, Jeremy S. Abramson, Cassie Dong, Frank Campana, Keenan Fenton, Markus Puhlmann, David J. Straus

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: